TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29392283

Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelets in additive solution
Number of subjects: 790

Group type: COMPARATOR
Intervention: Platelets in plasma
Number of subjects: 790

Group type: COMPARATOR
Intervention: Platelets in additive solution
Number of subjects: 790

Group type: COMPARATOR
Intervention: Pathogen-reduced platelets in additive solution vs platelets in plasma
Number of subjects: 790

Group type: COMPARATOR
Intervention: Pathogen-reduced platelets in additive solution vs platelets in additive solution
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 790
Study: 26712560

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 6 months
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 6 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: ranibizumab PRN
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ranibizumab PRN plus laser
Number of subjects: 81
Study: 24475026

Group type: EXPERIMENTAL
Intervention: 250 mg oral rilapladib once daily for 14 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 22884658

Group type: EXPERIMENTAL
Intervention: Laparoscopic dermoid cystectomy by mesial incision (33 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Laparoscopic dermoid cystectomy by antimesial incision (34 patients)
Number of subjects: 67
Study: 19284121

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg of ideal weight)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg of real weight)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg of ideal weight)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg/kg of real weight)
Number of subjects: 80
Study: 17873530

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole (as preoperative adjuvant therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with albendazole and PAIR
Number of subjects: 0
Study: 15692217

Group type: EXPERIMENTAL
Intervention: Iron saccharate complex (ISC), 100 mg twice weekly for 2 months and once weekly thereafter
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC), 62.5 mg twice weekly for 2 months and once weekly thereafter
Number of subjects: 48
Study: 12667322

Group type: EXPERIMENTAL
Intervention: Pituitrin infusion (2 U/min) during gastroduodenal artery blockage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline infusion (10 ml at 4 ml/min) as control
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trial group vs Control group
Number of subjects: 40
Study: 9707191

Group type: EXPERIMENTAL
Intervention: 100 mL HS‐HES
Number of subjects: 9

Group type: COMPARATOR
Intervention: 40 g mannitol
Number of subjects: 9
Study: 7661873

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/g)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of Pravastatin and Gemfibrozil (40 + 1200 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2756983

Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: No pyloroplasty (Control)
Number of subjects: 24
Study: 601437

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 50
Study: 31704740

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily plus vitamin K2 2000 µg thrice weekly
Number of subjects: 132

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs) with target INR 2‐3
Number of subjects: 132
Study: 29485197

Group type: EXPERIMENTAL
Intervention: EIT‐4‐BPSD
Number of subjects: 50

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 50
Study: 27722840

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 618
Study: 24509986

Group type: EXPERIMENTAL
Intervention: Repeated Sprint Ability Training (RST)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent Training (IT)
Number of subjects: 16
Study: 23812272

Group type: EXPERIMENTAL
Intervention: Propofol infusion of 2 mg/kgBW/h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo infusion (control group)
Number of subjects: 36
Study: 20151997

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doubling atorvastatin to 80 mg
Number of subjects: 0
Study: 18648776

Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein (HPROT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pure tryptophan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intact alpha-lactalbumin protein (ALAC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo protein
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tryptophan-containing synthetic peptide
Number of subjects: 18
Study: 16491133

Group type: EXPERIMENTAL
Intervention: Reboxetine plus 400 mg celecoxib for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reboxetine plus placebo for 6 weeks
Number of subjects: 40
Study: 12881842

Group type: EXPERIMENTAL
Intervention: Motor imagery training program (imagined wrist movements and mental simulations using a mirror box apparatus)
Number of subjects: 2
Study: 11007240

Group type: EXPERIMENTAL
Intervention: Liver transplantation (OLT)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy (glucocorticoids, cyclosporin, FK 506)
Number of subjects: 193
Study: 8775364

Group type: EXPERIMENTAL
Intervention: In-line skating in the 'sitting' position (LS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: In-line skating (US)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Running (TR)
Number of subjects: 7
Study: 1523353

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg tid during 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo tid during 12 weeks
Number of subjects: 32
Study: 6498567

Group type: EXPERIMENTAL
Intervention: Group I: 0.65 MAC nitrous oxide (66% inspired) and 0.65 MAC isoflurane (0.75% end‐expired)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group II: 0.65 MAC nitrous oxide and 1‐1.2 MAC isoflurane (1.2‐1.4% end‐expired)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group III: Same as Group I with addition of fentanyl (2 micrograms X kg‐1) before skin incision and 1/8 of the initial dose every 15 minutes during surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group IV: Same as Group I with additional infusion of lidocaine (30 micrograms X kg‐1 X min‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group V: 0.65 MAC of nitrous oxide and fentanyl (7.5 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group VI: 0.65 MAC of nitrous oxide and fentanyl (15 micrograms X kg‐1) before skin incision with 1/8 of the initial dose every 15 minutes during the operation
Number of subjects: 60
Study: 31433108

Group type: EXPERIMENTAL
Intervention: Suture
Number of subjects: 35

Group type: COMPARATOR
Intervention: No Suture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Surgical Glue
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All Groups
Number of subjects: 35
Study: 30541460

Group type: EXPERIMENTAL
Intervention: Activate intervention
Number of subjects: 14
Study: 26251965

Group type: EXPERIMENTAL
Intervention: Metacognitive memory strategy training (MST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metacognitive attention-perceptual-motor training (APM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo training (PLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 0
Study: 24331986

Group type: EXPERIMENTAL
Intervention: 1440-nm Nd:YAG laser irradiation with conventional root canal retreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional root canal retreatment
Number of subjects: 40
Study: 21940213

Group type: EXPERIMENTAL
Intervention: Rest-pause method
Number of subjects: 14

Group type: COMPARATOR
Intervention: Protocol A (5 sets of 4 repetitions with 3 min inter-set rest)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Protocol B (5 sets of 4 repetitions with 20 s inter-set rest)
Number of subjects: 14
Study: 20581575

Group type: COMPARATOR
Intervention: Randomized phase II trial designs
Number of subjects: 0
Study: 17378454

Group type: EXPERIMENTAL
Intervention: Thick intermediate layer of resin-based composite (RBC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (without RBC)
Number of subjects: 12
Study: 15564275

Group type: EXPERIMENTAL
Intervention: Referral to a local-authority exercise referral scheme and written information
Number of subjects: 545

Group type: COMPARATOR
Intervention: Written information only (Control)
Number of subjects: 545
Study: 12392583

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9915276

Group type: EXPERIMENTAL
Intervention: Peritoneoscopic technique
Number of subjects: 148

Group type: COMPARATOR
Intervention: Surgical technique
Number of subjects: 148
Study: 7561435

Group type: EXPERIMENTAL
Intervention: Cloxacillin prophylaxis (n = 52)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis (2 g intravenously, n = 25)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No prophylaxis (n = 26)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall results from both studies
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Postoperative bacteriology sample
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Wound complications
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Preoperative presence of bacteria
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Anaerobe isolates preoperatively
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Aerobes cultured postoperatively
Number of subjects: 103
Study: 2405197

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 444

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 444
Study: 7382709

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy and surgery
Number of subjects: 298

Group type: COMPARATOR
Intervention: Surgery and postoperative radiation therapy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Surgery and postoperative radiation therapy plus radical radiation therapy (for oral cavity and oropharynx lesions)
Number of subjects: 298
Study: 31765664

Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Concentric cycling (CON)
Number of subjects: 24
Study: 31412242

Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) 1 g per day for 21 days
Number of subjects: 12
Study: 28978802

Group type: EXPERIMENTAL
Intervention: Yellow fever live‐attenuated vaccine (YFLAV)
Number of subjects: 68
Study: 25457173

Group type: EXPERIMENTAL
Intervention: Transillumination method using Trachlight
Number of subjects: 80

Group type: COMPARATOR
Intervention: Main-stem method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transillumination method
Number of subjects: 80
Study: 23761087

Group type: EXPERIMENTAL
Intervention: DEX implant 0.70 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: DEX implant 0.35 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 229
Study: 21041105

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (M6G)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 517
Study: 20168099

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 2 x 5 mg (5 mg intravenously at randomization and at month 12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 1 x 5 mg (5 mg intravenously at randomization and placebo at month 12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (at randomization and at month 12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both zoledronic acid regimens
Number of subjects: 0
Study: 17935572

Group type: EXPERIMENTAL
Intervention: Daily infant probiotic supplement for the first 6 months of life
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15453623

Group type: EXPERIMENTAL
Intervention: Topical benzydamine hydrochloride 3% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 11565814

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9389780

Group type: EXPERIMENTAL
Intervention: Oestradiol gel (1.0 mg of oestradiol daily, Divigel/Sandrena)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oestradiol delivering patch (50 micrograms oestradiol/24 h, Estraderm TTS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reference group (25 women without HRT)
Number of subjects: 120
Study: 8238177

Group type: EXPERIMENTAL
Intervention: ST waveform plus cardiotocogram
Number of subjects: 2434

Group type: COMPARATOR
Intervention: Conventional cardiotocogram
Number of subjects: 2434
Study: 3476718

Group type: EXPERIMENTAL
Intervention: 10% strontium chloride hexahydrate dentifrice
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29618017

Group type: EXPERIMENTAL
Intervention: Monthly practice for 6 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Three consecutive practices at 3, 5 and 6 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 49
Study: 26365335

Group type: EXPERIMENTAL
Intervention: S05985 (perindopril 5 mg and amlodipine 5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perindopril tert‐butylamine 4 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 30
Study: 24216317

Group type: EXPERIMENTAL
Intervention: Atorvastatin preloading (80 mg 12 h and 40 mg 2 h pre-PCI)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Usual care (atorvastatin 40 mg/day)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Atorvastatin preloading
Number of subjects: 499

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 499
Study: 23787061

Group type: EXPERIMENTAL
Intervention: Mindfulness in Schools Programme
Number of subjects: 522

Group type: COMPARATOR
Intervention: Usual school curriculum
Number of subjects: 522
Study: 20118154

Group type: EXPERIMENTAL
Intervention: PPCI with postconditioning
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional PPCI
Number of subjects: 118
Study: 18678958

Group type: EXPERIMENTAL
Intervention: Protocol A (100‐Hz, 450‐microsecond pulses for 5 minutes in a 3‐seconds‐on 3‐seconds‐off duty cycle)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 7

Group type: COMPARATOR
Intervention: Protocol B (60‐Hz, 250‐microsecond pulses for 5 minutes in a 10‐seconds‐on 20‐seconds‐off duty cycle)
Number of subjects: 7
Study: 16618403

Group type: EXPERIMENTAL
Intervention: 48 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Number of subjects: 455

Group type: COMPARATOR
Intervention: 72 weeks of peginterferon-alfa-2a (180 microg/wk) plus ribavirin (800 mg/day)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: 72 weeks of treatment for patients HCV-RNA positive at week 12
Number of subjects: 455
Study: 14563580

Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) at 0.06 mg/kg per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unfractionated heparin at 100 to 400 U/kg per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Activated protein C (APC)
Number of subjects: 19
Study: 11459333

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/day titrated to a maximum of 20 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9205772

Group type: EXPERIMENTAL
Intervention: Cordaflex 20 mg retard filmtablet
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control preparation (not specified)
Number of subjects: 31
Study: 7962316

Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pregnanolone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Allopregnanolone to Progesterone ratio
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pregnanolone to Progesterone ratio
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sum of Allopregnanolone and Pregnanolone to Progesterone ratio
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Correlations with plasma progesterone levels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Mood and behavioral symptoms correlation
Number of subjects: 27
Study: 3677542

Group type: EXPERIMENTAL
Intervention: Lamotrigine 240 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamotrigine 120 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lamotrigine (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=5)
Number of subjects: 30
Study: 30020317

Group type: EXPERIMENTAL
Intervention: Video assisted training (VAT)
Number of subjects: 12
Study: 28039902

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 214
Study: 25936312

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham apheresis
Number of subjects: 0
Study: 22318691

Group type: EXPERIMENTAL
Intervention: Rapid smoking (SS)
Number of subjects: 161
Study: 21659315

Group type: EXPERIMENTAL
Intervention: mQLAZT (modified quarter laser-assisted zona thinning)
Number of subjects: 647
Study: 18479977

Group type: EXPERIMENTAL
Intervention: Qualitative methods including interviews, focus groups, audio-recording recruitment interactions, and feedback sessions for RCT staff.
Number of subjects: 5

Group type: COMPARATOR
Intervention: ProtecT qualitative methods
Number of subjects: 5
Study: 16476149

Group type: EXPERIMENTAL
Intervention: T allele of G protein beta3 (GNbeta3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borderline personality disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Young depressed patients
Number of subjects: 0
Study: 12895329

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 3030

Group type: COMPARATOR
Intervention: Both doses of mifepristone
Number of subjects: 3030
Study: 10813501

Group type: EXPERIMENTAL
Intervention: S. haematobium infection
Number of subjects: 7710

Group type: EXPERIMENTAL
Intervention: S. mansoni infection
Number of subjects: 7710

Group type: EXPERIMENTAL
Intervention: Obstructive uropathy
Number of subjects: 7710

Group type: EXPERIMENTAL
Intervention: Ultrasonography-detected bladder lesions
Number of subjects: 7710

Group type: EXPERIMENTAL
Intervention: Hepatomegaly, splenomegaly, and periportal fibrosis (PPF)
Number of subjects: 7710
Study: 9197351

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment group (15 mg/kg/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 102
Study: 31160805

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block combined with subcutaneous perineal anaesthesia and intrarectal lidocaine gel
Number of subjects: 216

Group type: COMPARATOR
Intervention: Total intravenous anaesthesia
Number of subjects: 216
Study: 30756393

Group type: EXPERIMENTAL
Intervention: Short duration cryoballoon application (105 seconds)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Medium duration cryoballoon application (164 seconds)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Long duration cryoballoon application (224 seconds)
Number of subjects: 222
Study: 28062082

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention model (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment (Control group, n=30)
Number of subjects: 60
Study: 26604652

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (patient controlled intravenous analgesia)
Number of subjects: 35
Study: 23179591

Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 1)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 2)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Questionnaire distribution (Study 3)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 10000
Study: 21600087

Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride tablet
Number of subjects: 719

Group type: COMPARATOR
Intervention: Levofloxacin tablet
Number of subjects: 719
Study: 18716482

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary rehabilitation (Rehab)
Number of subjects: 56
Study: 15686288

Group type: EXPERIMENTAL
Intervention: Trained raters
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untrained raters
Number of subjects: 24
Study: 12868802

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks for four cycles
Number of subjects: 162

Group type: COMPARATOR
Intervention: CVAP (Control)
Number of subjects: 162
Study: 10470596

Group type: EXPERIMENTAL
Intervention: Amtolmetin guacyl 600 mg bid
Number of subjects: 64

Group type: COMPARATOR
Intervention: Diclofenac 50 mg tid
Number of subjects: 64
Study: 9112714

Group type: EXPERIMENTAL
Intervention: Health services utilization for low back pain in Quebec
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Specialized imaging techniques
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Initial specific diagnosis and proximity to a university hospital
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Access to specialists
Number of subjects: 2147